Division of Infectious Diseases

What Patient Safety Means To Us – Part 1

As mentioned on Monday, patient safety is a primary focus of our work, particularly in Infection Control and Epidemiology. To really highlight the commitment to this initiative, we wanted to share a series on what patient safety means to us and a few examples of how we have implemented that into our work.

 

Per Dr. Mark Rupp,  Division Chief and Medical Director of Infection Control & Epidemiology:

Patient safety, is the very reasonable expectation from our patients, that although in healthcare we do things that are inherently dangerous, we minimize the risk of harm as much as is possible.  Quite simply, we eliminate preventable harm.

In the Infection Control and Epidemiology Department our whole effort is dedicated toward minimizing the occurrence of healthcare associated infections (HAIs). 

In recent years at Nebraska Medicine we have taken aggressive measures to decrease central line associated bloodstream infections (CLABSI) and catheter-associated urinary tract infections (CAUTI).  We emphasize horizontal interventions which are measures that impact all patients or broad groups of patients – examples of horizontal interventions are hand hygiene, chlorhexidine bathing, and environmental cleaning and disinfection.  At the present time we are in the middle of a campaign to decrease infection due to Clostridium difficile and launching programs to further limit infections following surgery (surgical site infections).  Much of the work we do is behind the scenes and includes making sure the air is safe, the water is free of pathogens, and systems to provide clean and sterilized instruments and devices are working properly.” 

 

Dr. Angela Hewlett, Medical Director of Clinical Operations for the Biocontainment Unit,  Associate Medical Director of Infection Control & Epidemiology and Director of Infectious Diseases Outpatient Clinic said:

To me, ‘patient safety’ is the practice of doing everything we can to prevent harm from coming to our patients.  Patient safety protocols should be based on the best available scientific evidence and always be accompanied by education (for healthcare workers as well as patients).

 Examples:

  1. After it was noted that patients with fractures were placed on a variety of antibiotic regimens in an effort to prevent infections, I worked on a collaborative project with the Department of Orthopaedic Surgery to standardize antibiotic recommendations for patients with fractures.  We created an Epic order set, and conducted educational sessions with multiple physician groups, including the Emergency Department, Trauma Surgery and Orthopedics.  This evidence-based protocol will help with patient safety by ensuring that patients are receiving appropriate antibiotics and dosing for an appropriate amount of time. 
  2.  Chlorhexidine (CHG) bathing is a modality that has been shown to decrease healthcare-associated infections, and is a standard practice for all inpatients at UNMC.  Dr. Andrea Green and I created a survey of nursing staff to determine what barriers exist in regards to CHG bathing of patients.   We used the information generated from the survey to create education on the benefits of CHG bathing in an effort to increase compliance with this practice. 

 

Kim Hayes, RN and Infection Preventionist added her perspective with:

What does patient safety mean to me?  First and foremost, we must not harm our patients during the course of their treatment, either in our cares or with our devices.  We must be mindful that our patients were not always as we see them and their families have the expectation that we will keep them safe and not let harm come to them while they stay with us.

Two projects that I have been involved with were the CAUTI reduction team during which every nurse/tech in the facility was instructed in catheter insertion and appropriate catheter cares, supply lines were standardized and we updated our devices(sterile piston irrigation set).  The second was moving from the outdated split septum IV infusion sets and connectors to meet the industry standard with the needleless sets and connectors.  This was an enterprise wide change that touched every department and made IV treatment safer.  Alligator clips no longer popped off and infused medications into the bed linens, needles were no longer used in the system, so nurses are safer today as a result.  

Learn more about ID and Infection Control at UNMC.

 

 


 

Patient Safety Awareness Week

“4 in 10 Americans say they have experienced a medical error in their own care or in the care of a loved one.”

Preventable Harm is critical to reduce in healthcare. It is a major cause of death, disability and costs, therefore the Institute for Healthcare Improvement created an initiative of Patient Safety Awareness Week from March 11 to the 17th. The mission is to raise awareness among providers and patients alike, to recognize the paramount importance of patient safety and that no matter what, WE ARE ALL PATIENTS. We all want medical care that is both excellent and safe.

How can you get involved with the events this week?

Take the pledge to help reduce harm.

Join the webinar at 12pm Central time for Engaging Patients and Providers: Speaking Up for a Culture of Safety

Join the Twitter chat. #PSAW18 Friday March 18th from 11AM -12PM Central Time on  Building a Culture of safety.

Check out resources for your institution and other events here: http://www.unitedforpatientsafety.org/

Here in the realm of Infectious Diseases, much of our work surrounds efforts that directly impact, and improve, patient safety. From antibiotic stewardship aid in improving our drug choices while minimizing adverse events to choosing the right types of IV catheters to even what may seem mundane, like making sure hand washing is easy-to-do and DONE! Throughout this week, we will be posting thoughts on what patient safety means to us and projects we have worked on that focus on patient safety.  This will included a broader array of the invaluable team members helping us all work toward safer healthcare everyday.


 

Match Day – Congratulations and Best Wishes!

Today is the day in which “the MATCH” happens for our 2018 students. This morning, at 11 AM they will find out if they matched into a residency program and this Friday, March 16, they will find out where they matched. Match Day is a day full of anxiety, excitement and some trepidation as you find out if you need to move, what city and state you may be relocating to before entering years of medical training as a resident.

The Match is meant to remove pressure and bias from both students and institutions during the process of choosing a residency program, but it is laced with the unknown and lack of control of where you go, and what you do next. It is a unique right of passage for physicians as they launch into the years of training after earning their MD.

Congratulations to medical students at UNMC and across the country as you celebrate and take the next steps toward becoming the future of medicine. No matter the result, you have come this far and you will continue to step forward as a physician into a realm of extraordinary opportunity to witness, and care for humanity, with all of it’s vulnerability and complexity.

From the UNMC ID Division, we wish you all the best and of course, we hope to see you join us again as fellows!


 

Happy International Women’s Day! Meet the Women Faculty of UNMC ID

March 8, International Women’s Day, was created as a day to recognize the women’s rights movements around the world. This year’s theme is #PressforProgress, fueled by ongoing global activism and advocacy for women’s rights in all facets of life.

In an age where more women than men are enrolled in US medical schools, and 52% of adult Infectious Disease Fellows are women,  young aspiring female doctors may look to the composition of faculty in their desired specialty as an indication of their likelihood to “fit in” with that specialty.  UNMC ID is a division that embodies #PressforProgress. Of 21 Faculty members within our division, 12 are women, and we are proud of every one of them.

Meet the Women Faculty of UNMC ID:

Dr. Sara Hurtado Bares, MD is an Assistant Professor of Medicine and Associate Director of the Specialty Care Clinic which serves our patients living with HIV. Her primary research and clinical interests lie with HIV prevention, and she is currently principal investigator of several studies looking at delivery of HIV pre-exposure prophylaxis to high-risk patients. Dr. Bares is also passionate about medical education; she is the director of the HIV track of the UNMC College of Medicine Enhanced Medical Education Tracks Course and co-directs the medical student microbiology/infectious disease courses called Defenses & Invaders with Dr. Andrea Zimmer.

Dr. Kelly Cawcutt, MD is an Assistant Professor of Medicine and Associate Medical Director of Infection Control and Epidemiology.  She is also a board-certified Critical Care Physician, and regularly attends on the ICU services at UNMC. Dr. Cawcutt is also creator and co-administrator of the UNMC ID Social Media platforms with Dr. Jasmine Marcelin, and recently published a commentary on the value of Social Media in academic medicine.

Dr. Razan El-Ramahi, MBBS is an Assistant Professor of Medicine.  Her clinical and research interests include infections in Oncology/Immunocompromised patients. She also attends on the inpatient Oncology Infectious Disease service and sees patients in the General Infectious Diseases clinic.

Dr. Diana Florescu, MD is an Associate Professor of Medicine. Dr. Florescu’s clinical and research interests include infections in solid organ transplant recipients. She attends on the inpatient Transplant Infectious Diseases service and is regularly involved in teaching residents and fellows.

Dr. Alison Freifeld, MD is a Professor of Medicine. Her clinical and research expertise lies in the Oncology/Immunocompromised patients, and she is the founder and Director of the Oncology Infectious Disease Service at UNMC. Dr. Freifeld is internationally known in her field and has published/edited several books, countless peer-reviewed publications, including authoring the Clinical Practice Guidelines for Management of Febrile Neutropenia. Dr. Freifeld sees immunocompromised patients with infections in the outpatient clinic, and works closely with oncologists at UNMC.

Dr. Andrea Green Hines, MD is an Assistant Professor in the departments of Internal Medicine and Pediatrics, and Medical Director of the Antimicrobial Stewardship Program at Children’s Hospital & Medical Center. Dr. Green Hines is also the Program Director of the Pediatric Infectious Diseases Fellowship Program at UNMC. Her clinical practice comprises both adult and pediatric medicine. She attends on the Oncology Infectious Diseases and Pediatric Infectious Diseases services at UNMC and the Pediatric Infectious Disease Service at Children’s Hospital & Medical Center. Her research interests include antimicrobial stewardship in pediatric populations.

Dr. Angela Hewlett, MD is an Associate Professor of Medicine and Associate director of Infection Control and Epidemiology. Dr. Hewlett is also the Medical Director of the Nebraska Biocontainment Unit which was selected to care for Americans affected by the recent Ebola epidemic in West Africa. Her work with the BCU allows her to collaborate with the Department of Justice and Department of Health and Human Services to ensure that personnel are always trained to be ready for any possible global health threat. Dr. Hewlett also has an interest in Orthopedic Infectious Diseases, which comprises much of her outpatient clinical practice. She attends on the inpatient General Infectious Disease service, and is an adviser for the medical student ID interest group on campus.

Dr. Jasmine Riviere Marcelin, MD is an Assistant Professor of Medicine and Associate Medical Director of the Nebraska Medicine Antimicrobial Stewardship Program. Her clinical and research interests include HIV treatment and prevention and Antimicrobial Stewardship.  She is passionate about medical education and co-directs the HIV track of the UNMC College of Medicine Enhanced Medical Education Tracks Course with Dr. Sara Bares.  She is also co-adminstrator of the UNMC ID Social Media platforms with Dr. Kelly Cawcutt and is passionate about improving diversity in medicine.

Dr. Kari Neemann, MD is an Assistant Professor in the departments of Medicine and Pediatrics. Like Dr. Green Hines, Dr. Neemann’s clinical practice comprises both adult and pediatric medicine. She attends on the Oncology Infectious Diseases and Pediatric Infectious Diseases services at UNMC and the Pediatric Infectious Disease Service at Children’s Hospital & Medical Center. Her research interests include infections in children and in adults with cancer.

Dr. Kimberly Scarsi, PharmD is an Associate Professor of Pharmacy. Her clinical practice is as an HIV pharmacist at the Specialty Care center. She also facilitates the Infectious Disease sections of the School of Pharmacy, and precepts the ambulatory clinic rotation for pharmacy students. Dr. Scarsi’s  primary research focus is on pharmacologic studies of treatments for HIV, focusing on women living with HIV and treating co-infections with HIV/TB, and she collaborates with Dr. Swindells and Dr. Bares on many local, multi-center and multinational research projects.

Dr. Susan Swindells, MBBS is a Professor of Medicine and Director of the Specialty Care Clinic which serves our patients living with HIV. She was honored as a Distinguished Scientist at UNMC in 2011, and in 2013 received the UNMC Innovation, Development and Engagement Award (IDEA) award. Her clinical and research interests include treatment of persons living with HIV and persons co-infected with HIV and Tuberculosis.  Dr. Swindells is on the writing group for the Department of Health & Human Services HIV guidelines as an HIV/TB co-infection content expert, and the Principal Investigator on a multinational study recently presented at the Conference on Retroviruses and Opportunistic Infections (CROI) that showed 1 month of treatment for latent TB infection is as effective as 9 months of treatment in persons living with HIV.

Dr. Andrea Zimmer, MD is an Assistant Professor of Medicine. Her clinical and research interests include infections in Oncology/Immunocompromised patients. She attends on the inpatient Oncology Infectious Disease service and sees immunocompromised patients with infections in the outpatient clinic also. Dr. Zimmer is also involved with medical education and co-directs the medical student microbiology/infectious disease courses called Defenses and Invaders with Dr. Sara Bares.

Join us today on #InternationalWomensDay and everyday as we #PressforProgress and celebrate these women who are invaluable assets to our Faculty and Division. Learn more about the UNMC Division of Infectious Diseases here.


 

New Staff Spotlight – Danny Schroeder, PharmD

Tell us about the position you are starting:  I have recently started my role at Nebraska Medicine Bellevue as an Antimicrobial Stewardship pharmacist. I reach out to physicians at Nebraska Medicine Bellevue to discuss antibiotic therapy and try to obtain the best and safest therapy for our patients here. In addition, I work with Dr. Jasmine Marcelin in this role, she helps guide me with her expertise on some of Bellevue’s more complicated patients.

Tell us about your background:  I was born and raised in Omaha, Nebraska. I completed my pre-pharmacy studies at the University of Nebraska at Lincoln and came back to Omaha and obtained my PharmD in 2012 at the University of Nebraska Medical Center College of Pharmacy. I started at Nebraska Medicine Bellevue right after I graduated in 2012 as a casual pharmacist and started my full time position at Bellevue in early 2013.

Why UNMC? I obtained my PharmD at UNMC so I already knew how great of an organization UNMC is. I knew once I graduated that if I had a chance to get a position at UNMC I would take it. Everyone I know that works for the organization is happy working here and I enjoy working with all of the staff from UNMC as well. I also have an interest in teaching so working at an academic institution can help me pursue that interest.

What about ID makes you excited?  As I have been working at Nebraska Medicine Bellevue I found that the patients that have interested me most have been patients with infections. Progress notes from ID attending physicians have always been my favorite notes to read because it is fascinating to me how they go about figuring out what is wrong with their patients. I am excited to join the detective crew and do my part to help tackle these cases. In addition, I feel like I learn something new in the ID realm every day, there are advancements and new therapies introduced often and I am always eager to learn new treatment mechanisms.

Tell us something interesting about yourself UNRELATED to medicine: I really enjoy having a good beer. My wife and I traveled to Germany in 2016 and we attended an Oktoberfest celebration in Stuttgart. I also enjoy outdoor activities like hiking and disc golf. Lastly, I am a dog person, my wife and I have two Shih Tzus and they take up a lot of our time!

 

Danny Schroeder is joining the Nebraska Medicine Antimicrobial Stewardship Program (ASP) Team as an ASP Pharmacist primarily located at our Bellevue campus. We are pleased to have the opportunity to add this ASP complement to our Bellevue campus – Danny has been a great asset to the team.

CROI 2018 – The Official UNMC ID Guide of Where We Will Be!

CROI 2018 is here and we want to be sure YOU know where to find us in Boston. Below is the list of faculty presentations and posters from our Division. Come visit us at CROI – We would LOVE to meet you! Find us on Twitter @UNMC_ID ; #UNMCID

Content courtesy of Kim Scarsi, Sue Swindells and the entire HIV group at UNMC ID

Oral presentations:

Monday March 5 2018, 11:15am (in Oral Abstract O-02 ART: New Data and new insights, Auditorium) 

Abstract 27: COMPARATIVE LYMPHOID TISSUE PHARMACOKINETICS (PK) OF INTEGRASE INHIBITORS (INSTI) 

Courtney V. Fletcher, Ann Thorkelson, Lee Winchester, Timothy Mykris, Jon Weinhold, Kayla Campbell, Jodi Anderson, Jacob Zulk, Puleng Moshele, Timothy Schacker

*****

Monday March 5 2018, 11:40 AM to 11:50 AM (in Oral Abstract O-03: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION, Ballroom C)

Late-Breaker Abstract 37LB: ONE MONTH OF RIFAPENTINE/ISONIAZID TO PREVENT TB IN PEOPLE WITH HIV: BRIEF-TB/A5279 

Susan Swindells, Ritesh Ramchandani, Amita Gupta, Constance A. Benson, Jorge T. Leon-Cruz, Ayotunde Omoz-Oarhe, Marc Antoine Jean Juste, Javier R. Lama, Javier A. Valencia, Sharlaa Badal-Faesen, Laura E. Moran, Courtney V. Fletcher, Eric Nuermberger, Richard E. Chaisson (presenter)

*****

Monday March 5 2018, 1:30pm (in Themed Discussion TD-02, Room 304-306, “Clinical Pharmacology of HIV-TB coinfection”)

Abstract 455: EFAVIRENZ PHARMACOKINETICS IN HIV/TB COINFECTED PERSONS RECEIVING RIFAPENTINE

Anthony Podany, Erin Sizemore, Michael Chen, Neil A. Martinson, Rodney Dawson, Sharlaa Badal-Faesen, Sachiko Miyahara, Ekaterina Kurbatova, William C. Whitworth, Richard E. Chaisson, Susan E. Dorman, Payam Nahid, Kelly Dooley, Susan Swindells, for the AIDS Clinical Trials Group & Tuberculosis Trials Consortium A5349 / Study 31 Team

*****

Wednesday March 7 2018, 11:30am (in the Oral Abstract session O-12, Ballroom C “Critical Issues in women’s health and early treatment of pediatric HIV infection”)

Abstract 141: VAGINAL CONTRACEPTIVE HORMONE EXPOSURE PROFOUNDLY ALTERED BY EFV- AND ATV/R-BASED ART

Kimberly K. Scarsi, Yoninah S. Cramer, David Gingrich, Susan L. Rosenkranz, Francesca Aweeka, Robert Coombs, Carmen D. Zorrilla, Kristine Coughlin, Laura E. Moran, Baiba Berzins, Catherine Godfrey, Susan E. Cohn, for the AIDS Clinical Trials Group A5316 Study Team

*****

Poster Presentations:

Monday March 5 2018, 2:30-4pm (Poster P-F1 ANTIRETROVIRAL, ANTITUBERCULAR, AND ANTIMALARIAL PHARMACOKINETICS Poster Hall D)

Abstract 455: EFAVIRENZ PHARMACOKINETICS IN HIV/TB COINFECTED PERSONS RECEIVING RIFAPENTINE

Anthony Podany, Erin Sizemore, Michael Chen, Neil A. Martinson, Rodney Dawson, Sharlaa Badal-Faesen, Sachiko Miyahara, Ekaterina Kurbatova, William C. Whitworth, Richard E. Chaisson, Susan E. Dorman, Payam Nahid, Kelly Dooley, Susan Swindells, for the AIDS Clinical Trials Group & Tuberculosis Trials Consortium A5349 / Study 31 Team

*****

Tuesday March 6 2019, 2:30-4pm: (Poster P-F3 ANTIRETROVIRAL PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTIONS, Poster Hall D)

Abstract 466:  CYP2B6 VARIANTS ALTER ETONOGESTREL PHARMACOKINETICS WHEN COMBINED WITH EFAVIRENZ

Megan Neary, Catherine Chappell, Kimberly K. Scarsi, Shadia Nakalema, Joshua Matovu, Sharon L. Achilles, Beatrice A. Chen, Marco Siccardi, Andrew Owen, Mohammed Lamorde

See you there!


 

JwXzvb KffZiDXoUreAyhbnT

Stewardship-driven Ertapenem Restriction: Can Reduced Utilization Affect the Antibiogram?

In this article review we learn about the impact of a large-scale, multi-institutional Antimicrobial Stewardship Intervention on significantly reducing the overall use of ertapenem without subsequent downstream effect on carbapenem-resistant Enterobacteriaceae (CRE) non-susceptibility patterns.

Delgado A, Gawrys GW, Duhon BM, Lee GC (2017). Impact of an Antimicrobial Stewardship Initiative on Ertapenem Use and Carbapenem Susceptibilities at Four Community Hospitals. J Infect Dis Ther 5: 341. doi:10.4172/2332-0877.1000341

Ertapenem has no activity against Pseudomonas spp. isolates, and although there is a theoretical risk of increasing carbapenem resistant Pseudomonas spp. isolates with ertapenem use, clinical studies have demonstrated that this is not the case.  Nevertheless, ertapenem use can potentially select for CRE, and there remains clinical value in minimizing its use.

The authors conducted a retrospective pre-post quality improvement study designed to reduce ertapenem usage, hoping to also demonstrate an effect in the prevalence of resistant Pseudomonas spp. and Enterobacteriaceae as a result of this intervention.  The multifaceted stewardship intervention was largely educational, but was supported by modification of electronic orders and providing audit-feedback opportunities to high frequency prescribers. They also included as a counter measure, evaluation of use of other alternative antimicrobials.

Copyright: © 2017 Delgado A, et al. Click to enlarge

They were successful in significantly reducing ertapenem utilization by 60% with mean days of therapy (DOT) per 1000 adjusted patient days declining from 17.6 to 7.0, p<0.001. There was a decrease in overall antibiotic use but as expected, ceftriaxone and fluoroquinolones were highly utilized and increased around October 2014 (3 months after electronic alert restricting ertapenem).  They reported stability of carbapenem use as a class.  They only reviewed Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae isolates; so potential effect on other Enterobacteriaceae could not be assessed. There was no change in % of P. aeruginosa non-susceptibility to carbapenems, however the average incidence of carbapenem non-susceptible P. aeruginosa isolates per 10,000 adjusted patient days decreased from 4.9 to 3.7 (p=0.03). There were no changes in % or average incidence of carbapenem non-susceptible E. coli or K. pneumoniae.

Copyright: © 2017 Delgado A, et al. Click to enlarge.

The authors achieved the goal of reduced ertapenem usage from 18.3 to 5.1 DOT, but did not show an associated change in carbapenem non-susceptible organisms. Furthermore, their overall carbapenem use was stable (though appears to have slightly trended upwards on the graph) despite significant ertapenem utilization reductions; without a breakdown of individual carbapenem use, it is impossible to know if there was a concordant increase in imipinem/meropenem use to account for this.  Antibiotic shortages occurred during the study period, which unfortunately adds a confounder to the overall reduction of antibiotic utilization, as well as overall carbapenem utilization. – could these shortages have caused an increase in meropenem use? Additionally, limited (though number not specified)  carbapenem non-susceptible isolates at baseline makes it difficult to draw conclusions about effect of the intervention on the antibiogram. However, it demonstrates well that a multifaceted intervention can have significant impact on antibiotic utilization.


 

Pharm to Exam Table – Trimethroprim/Sulfamethoxazole for Nocardiosis

Pharm to Exam Table: Clinical Pharmacology/Antibiotic Updates – Trimethroprim/Sulfamethoxazole for Nocardiosis

Nocardia is an aerobic, gram-positive bacterium commonly found in soil, decomposing vegetation, fresh water, and salt water. Nocardia is typically considered an opportunistic pathogen, but there have been several cases of nocardiosis occurring in immunocompetent hosts. Patients that are most at risk of developing nocardiosis are those with malignancies, human immunodeficiency virus (HIV), solid-organ and hematopoietic stem cell transplants, and long-term use of cell depleting medications such as corticosteroids. Nocardia infections most commonly present as a pulmonary infection, but may also include central nervous system involvement and skin abscesses. Nocardiosis usually requires a long course of treatment and traditionally, trimethoprim/sulfamethoxazole (TMP/SMX) has been the drug of choice.

Although there are numerous case reports available about the treatment of Nocardia infections, the lack of randomized controlled trials hinder the ability to make concise recommendations on drug dosing and treatment duration. Regardless of the site of infection, high dose TMP/SMX (800mg/160mg) given twice a day seems to be the most effective for eradicating Nocardia infections. The duration of treatment varies based on the location of the infection. Pulmonary infections should be treated for at least 3 months upon hospital discharge. Extending that duration to 6 months may also be appropriate if the patient is not responding as quickly or abscesses are still present on the CT exam at follow-up. Brain infections should be treated for at least 12 months upon hospital discharge. Cutaneous infections should be treated for at least 2 months. As with any of these infections, patients should be started on treatment as soon as Nocardia infections are identified. One area of variability is the amount of time patients are treated while inpatient because it will take each patient a different amount of time to become stable enough to discharge. The impact of the variation of overall treatment duration still remains unknown in the treatment of Nocardia. These recommendations are based on individual case studies and while they can be applied to other similar cases, it is important to take into account that additional agents may need to be added or substituted if susceptibility testing demonstrates resistance to TMP/SMX.

References

  1. Wilson JW. Nocardiosis: Updates and Clinical Overview. Mayo Clinic Proceedings. 2012 April; 87(4); 403-407.
  2. Valdezate S, Garrido N, Carrasco G, Medina-Pascual M, Villalon P, Navarro A, et al. Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain. Journal of Antimicrobial Chemotherapy. 15 Dec 2016; 72: 754-761.
  3. Galacho- Harriero A, Delgado-Lopez P, Ortega-Lafont M, Martin-Alonso J, Catilla-Diez J, et al. Nocardia farcinica Brain Abscess: Report of 3 Cases. World Neurosurgery. 18 July 2017.
  4. Sharrif M, Gunasekaran J. Pulmonary Nocardiosis: Review of Cases and an Update. Canadian Respiratory Journal. 9 November 2015.
  5. Zhu, N, Zhu, Y, Wang Y, Dong S. Pulmonary and cutaneous infection caused by Nocardia farcinica in a patient with nephrotic syndrome. Medicine. 16 May 2017; 96:24(e7211).

Content Courtesy Patricia Malinowski Burch, University of Nebraska Medical Center Pharmacy Student

Thank A Resident Day 2018 has ARRIVED

We recently posted about Resident Awareness Week in Canada and we are THRILLED to support this new initiative today.

Nebraska Medicine, UNMC and The Gold Humanism Honor Society are excited to celebrate all Residents today on Thank a Resident Day. Thank a Resident Day offers faculty and students the chance to show their gratitude to the unsung teachers of their medical school clerkship, the house-staff. 

While Residency is an important stage in medical training, it is also a period of peak burn out. Physician burnout affects more than half of U.S. doctors. Burnout is characterized by three symptoms; exhaustion, cynicism or dehumanization, and sense of ineffectiveness and lack of accomplishment. Thank a Resident Day is meant to Celebrate Residents and Explore their Resiliency. This is a medical-student led activity that will provide residents with resiliency-promoting physical and social activities as well as show support for their efforts.

A simple, but heart-felt, thank you may carry a larger impact than any of us realize. Please take a moment today to personally thank a resident. 

 

Here in the ID world, we would like to extend a particular thanks to our residents here in ALL specialties at UNMC. Thank you for EVERYTHING you do to help prevent and treat infections in the community and here in the hospital. We need your help every day in preventing the spread of disease, in antimicrobial stewardship and in providing the best possible care for our patients.


 

Honoring Black Women and Men Physician Leaders in Infectious Diseases

African Americans account for only 6% of newly minted doctors graduating from medical school in the USA. Within our specialty of Infectious Diseases, only 3% of ID physician members of the Infectious Diseases Society of America (IDSA) self-report as Black/African American. Many of these physicians make it their career goals to provide care for and advance clinical research pertaining to People of Color, often underrepresented in clinical trials and underserved in clinical practice.

In honor of Black History Month, let us recognize and honor Black Women and Men Physician Leaders who have and continue to advance our specialty.

Dr. William Augustus Hinton (1883-1959) was a microbiologist, and would be considered an Infectious Diseases Physician before the field of Infectious Diseases existed as a separate specialty. The son of two former freed slaves, Dr. Hinton graduated with honors from Harvard Medical College in 1912; by 1915 he had become the lab director for the Massachusetts State Department of Health. He went on to become the first African American to be appointed Professor at Harvard Medical School. His contributions to the field of Infectious Diseases were primarily regarding diagnosis and treatment of syphilis, which he worked on in his lab after being denied a medical internship due to his race. He developed a diagnostic test for syphilis called the Hinton test, a precipitation assay that was the most accurate of its time (later replaced by the RPR). He founded a school for women laboratory technicians, leading to countless job opportunities for hundreds of women. In 1936, Dr. Hinton was the first African American to publish a medical textbook: Syphilis and Its Treatment. Dr. Hinton’s legacy has been honored by the creation of the American Society of Microbiology William A Hinton Research Training Award dedicated toward research training of underrepresented minorities in microbiology.

Incidentally, his daughter, Dr. Jane Hinton (1919-2003) [photo not available] was one of the beneficiaries of Dr. Hinton’s Medical Laboratory Techniques course.  Before becoming one of the first African American woman veterinarians, she worked in Harvard laboratories to co-develop the Mueller-Hinton agar, which is still used today for antibiotic susceptibility testing. Infectious diseases doctors know that our jobs would be infinitely more difficult without antibiotic susceptibility testing.

There are over thirty-six million people worldwide living with HIV, twenty-five million of whom reside in African countries.  In the United States, 1.1 million people are living with HIV, and although African Americans make up only 12% of the entire US population, they account for 44% of the persons living with HIV in the USA. The doctors highlighted next have dedicated their lives to studying and caring for persons living with HIV. 

Drs. N’Galy Bosenge and Kapita Bila Minlangu were passionate doctors from Zaire (now known as the Democratic Republic of Congo), who led the charge towards understanding the HIV/AIDS epidemic in Africa. In 1984, Drs. N’Galy and Kapita were the Zairean co-leaders of Projet SIDA (Project AIDS), along with American ID physician scientist Dr. Jonathan Mann and other contributions from Belgian epidemiologists, the Centers for Disease Control and Prevention, and World Health Organization. Much of what we know about HIV/AIDS today can be traced back to early epidemiological studies and clinical research conducted at one hospital in Kinshasa.

Dr. N’Galy Bosenge led research and advocated for change in practices increasing risk for HIV transmission, particularly blood transfusions. Dr. N’Galy died tragically in a car accident in 1989, and for his early work in understanding HIV and establishing Projet SIDA, Dr. N’Galy is honored annually along with Dr. Mann at the Conference on Retroviruses and Opportunistic Infections (CROI) with the N’Galy-Mann lectureship.

Dr. Kapita Bila Minlangu has been credited as perhaps “one of the first African [doctors] to recognize the disease”, identifying individuals who he thought clinically were infected, so that the American/Belgian researchers could perform tests to confirm the diagnosis based on absence of T-helper cells.  These key observations led to the 1984 publication of data in The Lancet proving that HIV/AIDS was NOT a disease of gay men only, and that heterosexuals of all genders were susceptible to infection. Projet SIDA was discontinued abruptly in 1991 due to civil war in the country, but its impact on our understanding of HIV is still relevant today.

Dr. Kimberly Smith MD, MPH once referred to herself as “a trouble maker”.  Those three words tell a story about Dr. Smith spending her life advocating for women and children living with HIV (traditionally underrepresented in clinical studies), being a voice for those who cannot speak for themselves.  Dr. Smith’s invaluable contribution to the world of Infectious Diseases through research addressing gender and racial disparities among people living with HIV is evident by countless published papers on the topic. She has demonstrated her dedication to the community by her years of engagement in Chicago as a clinician.  Dr. Smith was awarded the Black AIDS Institute “Heroes in the Struggle” Award in 2008, the Thurgood Marshall College Fund Award of Excellence in Medicine in 2011, and in that same year, the HIV Medical Association (HIVMA) Clinical Educator Award. Dr. Smith is now the head of Global Research and Medical Strategy at ViiV Healthcare, the only pharmaceutical company 100% dedicated to providing treatment options for persons living with HIV. As head of this group, Dr. Smith has committed to including more women in clinical trials in order to improve the treatment of women living with HIV.

Adaora Adimora, MD, MPH, FIDSA, FACP: When asked for suggestions about names of African American ID physicians who have impacted our field, Dr. Adaora Adimora’s name was invariably on everyone’s list. She is a Professor of Medicine & Epidemiology at University of North Carolina. Dr. Adimora has been caring for persons living with HIV since the disease was first starting to be recognized, and her passion for caring for this patient population has not wavered. Her research career has identified socioeconomic and racial disparities in HIV infection and management, as well as other sexually transmitted diseases. She has been a leader in both research and clinical care of women living with HIV, who are often underrepresented in clinical research and prevention initiatives. Her commitment to HIV and clinical/research impact is internationally known. She was the program director of the Fogarty AIDS International Training and Research program at University of North Carolina from its inception in 1998, providing opportunities in HIV/AIDS for researchers from China, Cameroon and Malawi. A member of the US Department of Health and Human Services Antiretroviral Treatment Guidelines Panel, she was an instrumental author in multiple iterations of the Sexually Transmitted Infections Guidelines.  In 2014, she was appointed to President Obama’s Advisory Council on HIV/AIDS. In the same year, she was Chair of the HIV Medical Association (HIVMA).  In 2009 Dr. Adimora was named to the Root’s its inaugural list of The Root 100, an annual list of “the most influential African Americans ages 25-45…honoring the innovators, the leaders, the public figures and game changers whose work from the past year is breaking down barriers and paving the way for the next generation”.

Editorial note: This is obviously not an exhaustive list, but an introduction: As inspiring as these stories are, there are many others out there that are just as exceptional, and still others whose stories have yet to be told. Follow us on twitter @unmc_id to learn about them!

Acknowledgements: Many thanks to Drs. Wendy Armstrong and Igho Ofotokun, who shared some insights into African Americans who have influenced our field of Infectious Diseases. Other sources are included in hyperlinks throughout the post.

Image Sources:
Dr. Hinton: http://kentakepage.com/william-a-hinton-the-first-african-american-to-author-a-medical-textbook/ 
Drs. N’Galy and Kapita:  http://www.medizinisches-coaching.net/artikel/medical_coaching/projet-sida-kinshasa.html
Dr. Smith:  http://www.telegraph.co.uk/education/stem-awards/healthcare/working-on-a-cure-for-hiv/
Dr. Adimora: https://www.med.unc.edu/infdis/about/faculty/adaora-adimora-md